You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
|
|---|---|
| Published in |
Frontiers in oncology, February 2021
|
| DOI | 10.3389/fonc.2020.569715 |
| Pubmed ID | |
| Authors |
Daniel Morgensztern, Manuel Cobo Dols, Santiago Ponce Aix, Pieter E. Postmus, Jaafar Bennouna, Jürgen R. Fischer, Oscar Juan-Vidal, David J. Stewart, Andrea Ardizzoni, Rafia Bhore, Marianne Wolfsteiner, Martin Reck, Denis Talbot, Ramaswamy Govindan, Teng Jin Ong |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 33% |
| Switzerland | 1 | 33% |
| Italy | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 22 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 3 | 14% |
| Other | 2 | 9% |
| Researcher | 2 | 9% |
| Student > Doctoral Student | 1 | 5% |
| Lecturer | 1 | 5% |
| Other | 4 | 18% |
| Unknown | 9 | 41% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 32% |
| Biochemistry, Genetics and Molecular Biology | 2 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Agricultural and Biological Sciences | 1 | 5% |
| Business, Management and Accounting | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 10 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 November 2021.
All research outputs
#17,297,846
of 25,387,668 outputs
Outputs from Frontiers in oncology
#8,033
of 22,433 outputs
Outputs of similar age
#337,056
of 537,270 outputs
Outputs of similar age from Frontiers in oncology
#363
of 900 outputs
Altmetric has tracked 25,387,668 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,433 research outputs from this source. They receive a mean Attention Score of 3.0. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 537,270 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 900 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.